| Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer (NCT00536614) | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | 2005-05-01 |
| Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants (NCT00898482) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2005-05-01 |
| Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer (NCT00111904) | Theradex | 2005-05-01 |
| A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas (NCT00179751) | Celgene Corporation | 2005-04-01 |
| Randomized Controlled Trial on Pancreatic Stent Tube in Pancreaticoduodenectomy (NCT00628186) | Wakayama Medical University | 2005-04-01 |
| Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer (NCT00281996) | Northwestern University | 2005-03-01 |
| A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer (NCT00401570) | AbbVie (prior sponsor, Abbott) | 2005-03-01 |
| Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer (NCT00225784) | Dartmouth-Hitchcock Medical Center | 2005-02-01 |
| Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer. (NCT00159471) | University of Southern California | 2005-02-01 |
| Identification of Biomarkers for Early Detection of Pancreatic Cancer (NCT00897494) | Barbara Ann Karmanos Cancer Institute | 2005-02-01 |
| Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors (NCT00352131) | ImmunoGen, Inc. | 2005-02-01 |
| Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer (NCT00113256) | Astex Pharmaceuticals, Inc. | 2005-02-01 |
| ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer (NCT00102700) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2005-01-01 |
| Chemoradiation in Locally Advanced Pancreatic Cancer (NCT00262951) | Masonic Cancer Center, University of Minnesota | 2005-01-01 |
| Sirolimus in Treating Patients With Advanced Pancreatic Cancer (NCT00499486) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2005-01-01 |
| Fixed Dose Rate Gemcitabine and Cisplatin Followed by Chemoradiation for Locally Advanced Pancreatic Cancer (NCT01396668) | Seoul National University Hospital | 2004-12-01 |
| Adjuvant Gemcitabine and Cisplatin Followed by Chemoradiation for Resected Pancreatic Cancer (NCT01396681) | Seoul National University Hospital | 2004-12-01 |
| Gene Expression Profiles in Patients With Metastatic Pancreatic Cancer (NCT00897741) | Barbara Ann Karmanos Cancer Institute | 2004-12-01 |
| Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer (NCT00101907) | Amgen | 2004-12-01 |
| Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer (NCT00209677) | Hokkaido Gastrointestinal Cancer Study Group | 2004-12-01 |
| Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer (NCT00112658) | UNICANCER | 2004-11-01 |
| A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer (NCT00149578) | National Health Research Institutes, Taiwan | 2004-10-01 |
| Study of D-Methadone in Patients With Chronic Pain (NCT00588640) | Memorial Sloan Kettering Cancer Center | 2004-10-01 |
| Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer (NCT00185588) | George Albert Fisher | 2004-10-01 |
| Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer (NCT00268411) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2004-09-01 |
| Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer (NCT00099294) | Threshold Pharmaceuticals | 2004-09-01 |
| Safety and Efficacy Study of 90Y-hPAM4 at Different Doses (NCT00597129) | Gilead Sciences | 2004-08-01 |
| Blood Proteins in Finding Pancreatic Cancer and Extrahepatic Biliary Tract Cancer (NCT00559598) | National Institutes of Health Clinical Center (CC) | 2004-08-01 |
| Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer (NCT00266097) | UNC Lineberger Comprehensive Cancer Center | 2004-08-01 |
| Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer (NCT00100815) | Roswell Park Cancer Institute | 2004-08-01 |
| Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer (NCT00290693) | University of Miami | 2004-07-01 |
| Anastomotic Techniques in Pancreaticoduodenectomy (NCT00855985) | Lakeshore Hospital | 2004-07-01 |
| Gemcitabine With Curcumin for Pancreatic Cancer (NCT00192842) | Rambam Health Care Campus | 2004-07-01 |
| PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic Disease (NCT01102556) | Columbia University | 2004-07-01 |
| Study of CellCept for Advanced Pancreatic Cancer (NCT00997958) | Columbia University | 2004-06-01 |
| Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection (NCT00584363) | University of Alabama at Birmingham | 2004-06-01 |
| Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases (NCT00587964) | Memorial Sloan Kettering Cancer Center | 2004-06-01 |
| PANVACâ„¢-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen (NCT00088660) | Therion Biologics Corporation | 2004-06-01 |
| Standard and Immunostimulating Enteral Nutrition in Surgical Patients (NCT00576940) | Jagiellonian University | 2004-06-01 |
| Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer (NCT00463840) | NYU Langone Health | 2004-06-01 |
| Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma (NCT00600002) | Edward Nelson | 2004-06-01 |
| Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma (NCT00585078) | Beth Israel Deaconess Medical Center | 2004-05-01 |
| Doxil Topotecan Doublet Cancer Study (NCT00252889) | Christiana Care Health Services | 2004-05-01 |
| Chemoradiation-Induced Nausea and Emesis: Quality of Life (NCT00394602) | M.D. Anderson Cancer Center | 2004-04-07 |
| Ghrelin Levels in Pancreatic Cancer Patients (NCT00225745) | Dartmouth-Hitchcock Medical Center | 2004-04-01 |
| Chemotherapy With or Without Enoxaparin in Pancreatic Cancer (NCT00785421) | CONKO-Studiengruppe | 2004-04-01 |
| Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer (NCT00126633) | University of California, San Francisco | 2004-04-01 |
| 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer (NCT00078975) | University Health Network, Toronto | 2004-04-01 |
| A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01) (NCT00709462) | Celldex Therapeutics | 2004-03-01 |
| Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer (NCT00089024) | University of Nebraska | 2004-02-25 |
| Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors (NCT00096707) | Threshold Pharmaceuticals | 2004-02-01 |
| S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer (NCT00075686) | SWOG Cancer Research Network | 2004-01-01 |
| Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer (NCT00197431) | Hamamatsu University | 2004-01-01 |
| Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer (NCT00077519) | Abramson Cancer Center at Penn Medicine | 2004-01-01 |
| Pancreatic Adenocarcinoma Gene Environment Risk Study (NCT00912717) | University of Pittsburgh | 2004-01-01 |
| Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer (NCT00042939) | Eastern Cooperative Oncology Group | 2003-12-09 |
| Zinc Supplements in Lowering Cadmium Levels in Smokers (NCT00376987) | Wake Forest University Health Sciences | 2003-12-01 |
| Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer (NCT00068432) | M.D. Anderson Cancer Center | 2003-12-01 |
| Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer (NCT00316420) | Swedish Medical Center | 2003-12-01 |
| Preoperative Intratumor Dendritic Cells Injection Immunotherapy for Patients With Pancreatic Cancer (NCT00795977) | Fukushima Medical University | 2003-11-01 |
| Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma (NCT00075452) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2003-11-01 |
| Gemcitabine and Oxaliplatin Followed By Radiation Therapy, Fluorouracil, and Oxaliplatin in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery (NCT00275119) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2003-11-01 |
| Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer (NCT00049348) | Eastern Cooperative Oncology Group | 2003-10-13 |
| Radiation Therapy and Docetaxel With Either Fluorouracil or Cisplatin as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery (NCT00112697) | UNICANCER | 2003-10-06 |
| Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery (NCT00109941) | Milton S. Hershey Medical Center | 2003-10-01 |
| Tarceva and Capecitabine for Pancreatic Cancer (NCT00125021) | Dana-Farber Cancer Institute | 2003-10-01 |
| Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is Metastatic (NCT00490373) | Eli Lilly and Company | 2003-10-01 |
| Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer (NCT00066677) | Fox Chase Cancer Center | 2003-10-01 |
| Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer (NCT00057876) | Eastern Cooperative Oncology Group | 2003-08-29 |
| Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors (NCT00066651) | National Cancer Institute (NCI) | 2003-07-01 |
| Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer (NCT00233415) | Stanford University | 2003-07-01 |
| Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer (NCT00059982) | Eastern Cooperative Oncology Group | 2003-07-01 |
| Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery (NCT00335543) | Interdisziplinare Arbeitsgruppe Gastrointestinaler Tumore der Deutschen Krebsgesellschaft | 2003-06-01 |
| Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer (NCT00960284) | IRCCS San Raffaele | 2003-06-01 |
| Urine Cadmium Levels in Predicting Pancreatic Cancer Risk in Patients With Chronic Pancreatitis (NCT00489671) | Wake Forest University Health Sciences | 2003-06-01 |
| Perifosine in Treating Patients With Advanced Pancreatic Cancer (NCT00053924) | University Health Network, Toronto | 2003-05-01 |
| Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer (NCT00064207) | European Organisation for Research and Treatment of Cancer - EORTC | 2003-05-01 |
| Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT00462852) | Hull University Teaching Hospitals NHS Trust | 2003-04-01 |
| ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer (NCT00056537) | Active Biotech AB | 2003-04-01 |
| Benefit of Roux-en-Y (R-Y) Reconstruction After Pancreaticoduodenectomy (NCT00906802) | Kochi University | 2003-04-01 |
| Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer (NCT00108875) | Julius-Maximilians University | 2003-04-01 |
| Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer (NCT00059826) | Alliance for Clinical Trials in Oncology | 2003-03-01 |
| Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer (NCT00176813) | University of Michigan Rogel Cancer Center | 2003-03-01 |
| A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer (NCT02565641) | Hoffmann-La Roche | 2003-03-01 |
| Alanosine in Treating Patients With Cancer (NCT00062283) | Memorial Sloan Kettering Cancer Center | 2003-03-01 |
| Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT00058149) | Eastern Cooperative Oncology Group | 2003-03-01 |
| Pancreatic Cancer Collaborative Registry (NCT00661882) | University of Nebraska | 2003-02-01 |
| Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine (NCT00053222) | University of Chicago | 2003-02-01 |
| A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer (NCT00055250) | Eli Lilly and Company | 2003-01-01 |
| Pilot Safety Trial of Chemotherapy and Use of Heparin in Patients With Pancreatic Cancer (NCT01945879) | CONKO-Studiengruppe | 2003-01-01 |
| 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer (NCT00064051) | Vion Pharmaceuticals | 2003-01-01 |
| Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer (NCT00192712) | Rambam Health Care Campus | 2002-11-01 |
| Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer (NCT00031837) | Gary Morrow | 2002-10-01 |
| Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer (NCT00047710) | M.D. Anderson Cancer Center | 2002-09-01 |
| A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers (NCT00660699) | Washington University School of Medicine | 2002-09-01 |
| IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer (NCT00234416) | AstraZeneca | 2002-08-01 |
| Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer (NCT00082862) | The University of Texas Health Science Center, Houston | 2002-07-01 |
| Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract (NCT00012246) | The University of Texas Medical Branch, Galveston | 2002-07-01 |
| UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer (NCT00045747) | Memorial Sloan Kettering Cancer Center | 2002-07-01 |
| Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors (NCT00049608) | National Center for Complementary and Integrative Health (NCCIH) | 2002-07-01 |